Disease · MONDO_0006451

thymic carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. thymic carcinoma. Diseases, record MONDO_0006451. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006451

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: thymic carcinoma; Open Targets
Open Targets ID: MONDO_0006451; Open Targets
Other names: carcinoma of thymus, malignant thymoma, thymic carcinoma (excluding well differentiated thymic carcinoma), thymoma type C, thymoma, malignant, thymoma, malignant (morphologic abnormality), thymoma, type C (morphologic abnormality), thymus carcinoma, type C thymoma; Open Targets
Disease Ontology: DOID:3284; Disease Ontology
Disease Ontology: DOID:4554; Disease Ontology
NCI Thesaurus: C7569; NCI Thesaurus
NCI Thesaurus: C7612; NCI Thesaurus
Orphanet: ORPHA:99868; Orphanet
Highest stage of its drugs: Phase 3, for 4 of its 49 drugs, from ClinicalTrials.gov; Open Targets

Drugs49

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	6	6	6	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
SUNITINIB	CHEMBL535	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
BELINOSTAT	CHEMBL408513	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 49

See all 49 drugs

Targets73

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
CD274	Programmed cell death 1 ligand 1	4	Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other	Phase 2	https://conductscience.org/library/genes/29126	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	4	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDCD1	Programmed cell death protein 1	4	Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	4	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
ABL1	Bcr/Abl fusion protein	3	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 2	https://conductscience.org/library/genes/25	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	3	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	3	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 3	https://conductscience.org/library/genes/7153	Drugs and targets
TYMS	Thymidylate synthase	3	Thymidylate synthase inhibitor	Phase 3	https://conductscience.org/library/genes/7298	Drugs and targets

1 to 10 of 73

See all 73 targets

Trials49

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03583086	Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors	Phase 1/2	88	2024-10-08	Thymic Carcinoma, Non-small Cell Lung Cancer, Refractory Thoracic Tumors, Small-Cell Lung Cancer	NIVOLUMAB, VOROLANIB	Its record names the disease	ClinicalTrials.gov
NCT01011439	Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma	Phase 2	72	2018-10-16	Thymic Carcinoma	MILCICLIB	Its record names the disease	ClinicalTrials.gov
NCT01621568	Sunitinib for Advanced Thymus Cancer Following Earlier Treatment	Phase 2	56	2022-06-07	Thymoma, Thymus Neoplasms	SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT00965250	Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy	Phase 2	49	2012-11-14	Thymoma, Thymic Carcinoma, Thymic Carcinoid, Thymic Neuroendocrine Tumors	CIXUTUMUMAB	Its record names the disease	ClinicalTrials.gov
NCT00010257	Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma	Phase 2	46	2012-10-18	Thymoma, Thymic Carcinoma	CARBOPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT02364076	Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma	Phase 2	45	2019-12-13	Thymic Carcinoma, Thymus Neoplasms, Thymus Cancer	EPACADOSTAT, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00589290	Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage	Phase 2	41	2012-05-30	Thymoma, Thymic Carcinoma	BELINOSTAT	Its record names the disease	ClinicalTrials.gov
NCT01364727	A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies	Phase 2	33	2017-03-14	Thymoma, Thymus Cancer, Thymic Carcinoma	AMRUBICIN	Its record names the disease	ClinicalTrials.gov
NCT01301391	Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy	Phase 2	30	2018-10-04	Malignant Thymoma	MILCICLIB	Its record names the disease	ClinicalTrials.gov
NCT00198133	Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma	Phase 2	27	2016-01-25	Thymoma, Thymic Carcinoma	PEMETREXED	Its record names the disease	ClinicalTrials.gov

1 to 10 of 49

See all 49 trials

Comparisons in its trials11

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Treatment: Weeks 1-4, Group 1; Weeks 1-2, Group 2 vs No Treatment: Weeks 5-6, Group 1; Week 3, Group 2: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0).	41 of 41	15 of 15	56	NCT01621568	Trial comparisons
Treatment: Weeks 1-4, Group 1; Weeks 1-2, Group 2 vs No Treatment: Weeks 5-6, Group 1; Week 3, Group 2: deaths from any cause	38 of 41	15 of 15	56	NCT01621568	Trial comparisons
Treatment: Weeks 1-4, Group 1; Weeks 1-2, Group 2 vs No Treatment: Weeks 5-6, Group 1; Week 3, Group 2: serious adverse events	38 of 41	15 of 15	56	NCT01621568	Trial comparisons
Thymoma vs Thymic Carcinoma: serious adverse events	13 of 24	14 of 21	45	NCT00010257	Trial comparisons
Thymoma Patients vs Thymic Patients: Number of Participants With a Partial Response	2 of 25	0 of 16	41	NCT00589290	Trial comparisons
Thymoma vs Thymic Carcinoma: Grade 3/4 Treatment Related Adverse Events	1 of 16	1 of 11	27	NCT00198133	Trial comparisons
Thymoma vs Thymic Carcinoma: serious adverse events	2 of 16	3 of 11	27	NCT00198133	Trial comparisons
Thymoma vs Thymic Carcinoma: Expected Toxicities Including Skin Rashes and Diarrhea	10 of 12	3 of 9	21	NCT00718809	Trial comparisons
Thymoma vs Thymic Carcinoma: serious adverse events	2 of 12	1 of 9	21	NCT00718809	Trial comparisons
Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel) vs Active Comparator: Arm B (Carboplatin, Paclitaxel): deaths from any cause	1 of 8	2 of 9	17	NCT03694002	Trial comparisons

1 to 10 of 11

See all 11 comparisons in its trials

Papers from its trials62

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33248322	RESULT	1	PubMed
32502444	RESULT	1	PubMed
31772071	RESULT	1	PubMed
30991261	RESULT	1	PubMed
30207917	RESULT	1	PubMed
29906252	RESULT	1	PubMed
29438696	RESULT	1	PubMed
29395863	RESULT	2	PubMed
28759346	RESULT	1	PubMed
27876674	RESULT	1	PubMed

1 to 10 of 62

See all 62 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006451

GET https://conductscience.org/api/diseases/v1/MONDO_0006451/drugs?page=2

API reference For AI assistants